Camlin Fine Sciences approved the strategic investment in AlgalR NutraPharms by way of acquisition of equity shares amounting to 69.33% of the existing paid‐up share capital. The company also approved subscription to the equity shares of AlgalR upon consummation of the Secondary Purchase and Primary Subscription, the Company will hold 80% of the paid‐up capital of AlgalR on a fully diluted basis.